DM
Deerfield Management Portfolio holdings
AUM
$6.52B
1-Year Est. Return
13.67%
1 Year Est. Return
+13.67%
AUM
$6.52B
AUM Growth
+$1.02B
(+18%)
Holding
173
Top Buys
| 1 | +$209M | |
| 2 | +$130M | |
| 3 | +$105M | |
| 4 |
Cogent Biosciences
COGT
|
+$92.1M |
| 5 |
Inspire Medical Systems
INSP
|
+$67.4M |
Top Sells
| 1 | +$250M | |
| 2 | +$86.3M | |
| 3 | +$48.1M | |
| 4 |
IDEAYA Biosciences
IDYA
|
+$48M |
| 5 |
Baxter International
BAX
|
+$42.8M |
Sector Composition
| 1 | Healthcare | 91.92% |
| 2 | Real Estate | 0.38% |
| 3 | Financials | 0.07% |
| 4 | Consumer Staples | 0.07% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Universal Health Services
UHS
$12.5B
| – | – |
-1,597
|
|
||
152
PACS Group
PACS
$6.07B
| – | – |
-11,421
|
|
||
|
AMED
153
DELISTED
Amedisys
AMED
| – | – |
-2,744
|
|
||
154
Amphastar Pharmaceuticals
AMPH
$1.2B
| – | – |
-9,579
|
|
||
155
Charles River Laboratories
CRL
$10.8B
| – | – |
-43
|
|
||
156
Delcath Systems
DCTH
$360M
| – | – |
-812,561
|
|
||
|
HLVX
157
DELISTED
HilleVax
HLVX
| – | – |
-1,882,654
|
|
||
158
IQVIA
IQV
$40.5B
| – | – |
-1,623
|
|
||
159
Liquidia Corp
LQDA
$3.3B
| – | – |
-1,616,778
|
|
||
160
Medpace
MEDP
$17.2B
| – | – |
-736
|
|
||
|
MREO
161
Mereo BioPharma
MREO
$102M
| – | – |
-6,710,429
|
|
||
162
Moderna
MRNA
$16.3B
| – | – |
-1,000,000
|
|
||
163
Neuropace
NPCE
$564M
| – | – |
-500,000
|
|